I don’t believe in diets. But I do believe that MGUS patients can change their lifestyle, lose weight and reduce their risk of progressing to Multiple Myeloma. Further, the same diet and lifestyle therapies have been shown to both starve multiple myeloma while also being cytotoxic to MM. Talk about a win-win.
MGUS at a glance- click the illustration below:
The question is, can Monoclonal Gammopathy of Undetermined Significance patients reduce or eliminate his/her risk of their pre-MM progressing to MM? Yes, according to the short video linked below. According to the study talked about in the video, curcumin and diet can slow the progression of pre-MM to MM. In addition there are evidence-based therapies that act like curcumin does as an anti-oxidant, anti-inflammatory, etc. supplement.
I am both a long-term MM survivor and MM cancer coach. I have lived in complete remission from my multiple myeloma since 1999 by living an evidence-based, non-toxic, anti-MM lifestyle.
To learn more about the evidence-based protocols you can follow to prevent your Pre-Myeloma from becoming Multiple Myeloma, please watch the short video below:
If you do not want to “watch and wait” to see if your Monoclonal Gammopathy of Undetermined Significance progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.
Consider evidence-based, non-toxic therapies such as:
Thanks and hang in there,
Monoclonal Gammopathy of Undetermined Significance may progress to multiple myeloma, AL amyloidosis, Waldenstrom’s macroglobulinemia, or lymphoma. But not all cases progress to malignancy.
“Obesity and black race are associated with an increased risk for transformation of monoclonal gammopathy of undetermined significance to MM…
During a median follow-up of 68 months, 329 (4.2%) patients with Monoclonal Gammopathy of Undetermined Significance progressed to MM, including 72 (3.5%) normal-weight patients, 144 (4.6%) overweight patients, and 113 (4.3%) obese patients.
After adjusting for multiple variables, researchers found that obese patients had a nearly 2 times higher risk for progressing to MM than normal-weight patients…”
The Most BioAvailable Curcumin Formulas
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”